Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 17 Aug 2018 Primary endpoint (Disease Activity Score in 28 joints using 4 variables (C-reactive protein) has not been met, as per the results published in the Rheumatology
- 17 Aug 2018 Results published in the Rheumatology
- 16 Apr 2017 Status changed from active, no longer recruiting to completed.